Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens

The response of CRC patients to the combination regimen of 5-FU and L-OPH is heterogeneous. This study confirmed that the ATP-TCA is a valuable tool for predicting clinical outcomes, such as DFS, in patients with resectable CRC receiving chemotherapy. Although further validation with multicentre data is still necessary, these findings support that the ATP-TCA may function as a guiding tool for personalized chemotherapy administration, thereby optimizing treatment opportunities for patients.